Trial Profile
The Pharmacokinetics of Ledipasvir, an HCV Specific NS5A Inhibitor, in HCV-Uninfected Subjects with Severe Renal Impairment
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 31 Aug 2015
Price :
$35
*
At a glance
- Drugs Ledipasvir (Primary)
- Indications Hepatitis C
- Focus Pharmacokinetics
- Sponsors Gilead Sciences
- 31 Aug 2015 New trial record